PepTalk 2017 - The Protein Science Week

Date: 09 Jan 2017 Location: Hilton San Diego Bayfront City: San Diego, CA Country: USA Visit the event website for more information Booth 209





Laurent Ducry, Ph.D


Head, Bioconjugates R&D           
  Sunday, January 8, 2017 | 5:00 - 8:00 pm: Production Challenges for Complex Biologics: Antibody-Drug Conjugates and Fusion Proteins           

 This course addresses the typical production issues encountered with complex biologics, namely fusion proteins, antibody-drug conjugates and bispecific antibodies. Experts elucidate the structure and nature of these biologics in order to understand and master their properties. Along with exploring manufacturing challenges, the course also reveals how to overcome these challenges with practical insights and advice.



Stefan R. Schmidt, Ph.D., MBA, Vice President, Rentschler Biotechnology

Gang Gary Chen, Ph.D., Head, ADC Technology, Levena BioPharma

Laurent Ducry, Ph.D., Head, Bioconjugates R&D, Lonza 



Prof.Dr. Hanns-Christian Mahler

Prof. Dr. Hanns-Christian Mahler


Head, Drug Product Services            

  Tuesday, January 10, 2017 | 5:45-8:45 pm: Ensuring Accelerated and Successful Drug Product Development of Biologics: Integrated Formulation Development, Process and Packaging Design


Suitable biotech drug product design is key to the success of patient treatment. Formulation, manufacturing process and primary packaging are integral components of the drug product. In addition, a focus on management of the interface of drug substance to drug product is essential for efficient and successful development. This short course is designed to discuss strategies on how to approach an appropriate design for a target product profile, formulation, primary packaging and manufacturing process. Hot topics in drug product development, including particulates, aggregates, container closure integrity, surfactant stability and low endotoxin recovery, will be further discussed.


*Poster Presentation*

High-throughput Lonza: Presenting Lonza’s Advanced Automated Downstream Development Platform

Lonza has made significant investment in High-throughput robotics, spanning from early cell line selection to a full downstream purification train and associated analytics. We are using the High-throughput Lonza platform to develop flexible, adaptable processes that can serve a wider range of diverse products. We will showcase our automated downstream tools used for buffer stability screening for early indication of product quality risks, our future work on excipient screening for proactive stability checking of niche biologics such as intra-ocular products, and Mass spectrometry for the targeted removal of specific Host Cell Protein impurities. Tangible advantages for our customers and our vision for the future will be presented.



Hannah Shore, Downstream Process Scientist, Research & Technology, Lonza

Rita Tommasi, Ph.D., Associate Principal Scientist, Research & Technology, Lonza